THE COSTS OF TREATING FEBRILE NEUTROPENIA IN PATIENTS WITH MALIGNANT BLOOD DISORDERS

被引：22

作者：

LEESE, B

COLLIN, R

CLARK, DJ

机构：

[1] Centre for Health Economics, University of York, York

[2] Department of Haematology, Chesterfield and North Derbyshire Royal Hospital, Chesterfield

来源：

PHARMACOECONOMICS | 1994年 / 6卷 / 03期

关键词：

D O I：

10.2165/00019053-199406030-00007

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

Retrospective data were collected over a 1-year period from the medical records of patients admitted to a district general hospital, either with febrile neutropenia or who developed this complication whilst receiving inpatient chemotherapy. Costs were calculated for inpatient stay, drug treatment and diagnostic tests. The median total costs for 46 episodes of febrile neutropenia were 2068.35 Pounds and the median total cost per day was 139.41 Pounds. Inpatient bed-days accounted for 57.8% of total costs, followed by drug treatment at 25.8% and diagnostic tests at 16.4%. The costs of blood products were excluded since they are frequently administered irrespective of the neutropenia. This study serves as a useful pointer to the expenditure in measurable antibiotic costs and investigations in patients with malignant blood disorders who develop febrile neutropenia.

引用

页码：233 / 239

页数：7

共 12 条

[1]

Finch S.C., Neutrophil disorders–benign, quantitative abnormalities of neatrophils, Haematology, (1983)

[2]

Crawford J., Ozer H., Stoller R., Et al., Rceuction by grallulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer, N Engl J Med, 325, (1991)

[3]

Pizzo P.A., Current issues in the antibiotic primary management of the febrile:neutropenic cancer patient: a prospective from the:National Cancer Institution, J Hosp Infect, 15, (1990)

[4]

Gurney H., The problen of neutropenia resulting from cancer therapy, Clinician, 7, pp. 2-10, (1989)

[5]

Hollingshead L.M., Goa K.L., Recombinant granulocyte colony, stimulating factor: a review of its pharmacological properties and prospectitive role in neutropenia conditions, Drugs, 42, (1991)

[6]

Faulds D., Lewis N., Milne R.J., Recombinant granulocyte colony-stimulating factor: pharmacoecconomic considerations in chemotherapy-induced neutropenia, Pharmaco Economics, 1, (1992)

[7]

Chaplin S., Cancer therapy complication costly ti treat, Hospital Doctor, (1991)

[8]

Leese B., The costs of treating febrile neutropenia and tile potential savings from G-CSF, Health systems–the challenge of change, (1992)

[9]

Leese B., The costs of treating febrile neutropenia in six. UK hospitals, Eur J Cancer, 29 A, (1993)

[10]

Glaspy J.A., Bleecker G.C., Stoller R.G., Et al., Decrcased costs in ca~ncer chemotherapy patients using recombinant granulocyte colony-stimulating factor, Clin Res, 7, (1991)

← 1 2 →